NEW YORK and SHANGHAI, August 3, 2021 / PRNewswire / – WuXi STA – a subsidiary of WuXi AppTec – today announced that it has completed the acquisition of a pharmaceutical manufacturing plant in Couvet, Swiss from Bristol Myers Squibb (NYSE: BMY). WuXi STA first announced its intention to purchase the facility earlier this year. The acquisition will enhance WuXi STA’s capabilities by adding the ability to support its global partners in delivering innovative medicines to patients around the world.
The Couvet site is the first installation in Europe for WuXi STA. Opened in 2018, the advanced tablet and capsule manufacturing and packaging capabilities of this factory will provide WuXi STA customers with more flexibility through improved supply of global pharmaceuticals and better access to the European market and to- of the.
By improving its network, WuXi STA can better meet the long-term needs of customers globally, as they bring new and existing commercial manufacturing projects from their pipelines to the facility with the capacity and ability to deliver pharmaceutical products to major world markets.
“We are delighted to have added the Couvet site to our global supply network and are delighted to welcome its highly qualified team to the WuXi STA family” said Dr Minzhang Chen, co-CEO of WuXi AppTec. “By combining the resources of the Couvet site with our other facilities, we continue to strengthen and expand our capacities and capacities to better support our global customers in providing innovative medicines to patients in need. ”
Through this transaction, WuXi STA increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including recent announcement Middletown site in Delaware of United States.
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing company and technology platform serving the science industry. life, with global operations. As the premier contract development and manufacturing (CDMO) organization, WuXi STA provides its global partners with efficient, flexible and high-quality solutions for integrated chemistry, manufacturing and control (CMC), from preclinical uses to commercial uses.
For more information, please visit: https://www.STApharma.com
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable pharmaceutical, biotechnology and medical device companies around the world to advance discoveries and deliver breakthrough treatments to patients. As an innovation and customer-driven company, WuXi AppTec helps our partners to improve the productivity of advanced health products through cost-effective and efficient, socially responsible and sustainable solutions. With cutting-edge capabilities such as R&D and manufacturing of small molecule drugs, cell and gene therapies, and medical device testing, WuXi AppTec’s open access platform enables more than 4,400 employees from over 30 countries to improve the health of those in need. – and realize our vision that “every medicine can be made and every disease can be treated”. Please visit: www.wuxiapptec.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland-301346548 .html
SOURCE WuXi AppTec